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Abstract 
Aims: The clinical correlates and consequences of atrial fibrillation (AF) might be different between 
heart failure with reduced versus preserved ejection fraction (HFrEF vs. HFpEF). Biomarkers may 
provide insights into underlying pathophysiological mechanisms of AF in these different HF 
phenotypes. 
Methods and Results: We performed a retrospective analysis of the BIOlogy Study to TAilored 
Treatment in Chronic Heart Failure (BIOSTAT-CHF), which was an observational cohort. We studied 
2152 patients with HFrEF (EF<40%), of which 1419 were in sinus rhythm (SR) and 733 had AF. 
Another 524 patients with HFpEF (EF ≥50%) were studied, of which 286 in SR and 238 with AF. For 
the comparison of biomarker profiles, 92 cardiovascular risk markers were measured (Proseek® Olink 
Cardiovascular III panel). The circulating risk marker pattern observed in HFrEF was different than 
the pattern in HFpEF: in HFrEF, AF was associated with higher levels of 77 of 92 (84%) risk markers 
compared to sinus rhythm (SR); whereas in HFpEF, many more markers were higher in SR than in 
AF. Over a median follow-up of 21 months, AF was associated with increased mortality risk 
(multivariable hazard ratio [HR] of 1.27; 95% confidence interval [CI] 1.09-1.48, p=0.002); there was 
no significant interaction between heart rhythm and EF group on outcome.  
Conclusion: In patients with HFrEF, the presence of AF was associated with a homogeneously 
elevated cardiovascular risk marker profile. In contrast, in patients with HFpEF, the presence of AF 
was associated with a more scattered risk marker profile, suggesting differences in underlying 
pathophysiological mechanisms of AF in these HF phenotypes.  
 
Key words: Atrial fibrillation; heart failure; preserved ejection fraction; biomarkers.  
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Clinical perspective 
In patients with HFrEF, cardiovascular risk markers were homogeneously higher in AF patients 
compared to patients in SR. This was in contrast to patients with HFpEF, where the risk marker profile 
was more scattered. Even though these findings do not have direct clinical implications, these different 
risk marker profiles might suggest that AF has a different pathophysiological role in HFrEF than it has 
in HFpEF. A better understanding of this potential difference of AF in the two HF phenotypes should 
be further investigated, since this might also give insights into potential differences in (response to) 
treatment of AF in HFrEF versus HFpEF. Moreover, the differences in risk marker profiles could 
potentially be helpful in finding a biomarker (panel) that is more accurate in diagnosing HFpEF in 
patients with concomitant AF than currently recommended diagnostics that are not specific for AF nor 
HFpEF (a combination of signs and/or symptoms, elevated levels of NT-proBNP and structural or 
functional cardiac abnormalities assessed by echocardiography). Ideally, the biomarker pattern of 
patients with ‘pure’ AF (without HFpEF) should be compared to the markers of patients with HFpEF 
without AF, and those with both AF and HFpEF, in order to find a biomarker with a higher 
discriminative capacity than NT-proBNP has. 
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Abbreviations list 
AF = atrial fibrillation 
ECG = electrocardiogram 
HF = heart failure 
HFrEF = heart failure with reduced ejection fraction 
HFpEF = heart failure with preserved ejection fraction 
LVEF = left ventricular ejection fraction 
QoL = quality of life 
SR = sinus rhythm 
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Introduction 
Atrial fibrillation (AF) and heart failure (HF) share common risk factors, predispose to each other, and 
together herald a worse prognosis than either condition alone.(1-3) The majority of our knowledge on 
the AF-HF relationship stems from series based on HF with reduced ejection fraction (HFrEF). 
However, HF with preserved ejection fraction (HFpEF) accounts for up to half of HF diagnoses, and 
AF has a high prevalence in both HFrEF and HFpEF.(4-6)  
HFpEF is a more heterogeneous syndrome than HFrEF, with highly prevalent co-morbidities and a 
higher prevalence among elderly, obese, and women.(7) The diagnosis of HFpEF in the setting of AF 
is challenging because risk factors and symptoms overlap. Moreover, levels of biomarkers, such as 
circulating natriuretic peptides, are influenced by both AF and HF, which further complicates the 
diagnosis of HFpEF.(5,8) Therefore, in most current HF trials, separate cutoffs for these natriuretic 
peptides are used for patients in sinus rhythm (SR) and those in AF.(9) However, the specific cutoffs 
that are used are still arbitrary and widely debated. 
Since distinct differences in pathophysiology are seen between HFrEF and HFpEF, with pronounced 
differences in age, sex, etiology and response to therapy, it is possible that AF also plays a different 
role and reflects different pathophysiological processes in these HF phenotypes.(10-12) Biomarkers 
might have the potential to help us understand these possible differences in the underlying 
pathophysiological role of AF. Therefore, we performed a post-hoc analysis of BIOSTAT-CHF to 
study biomarker profiles of patients in AF versus SR in both HFrEF and HFpEF. 
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Methods 
Patient population and study design 
We performed a retrospective analysis of The BIOlogy Study to TAilored Treatment in Chronic Heart 
Failure (BIOSTAT-CHF), which was an observational study and has been previously 
published.(13,14) In brief, a total of 4254 patients with new-onset or worsening signs and/or 
symptoms of HF from eleven European countries were included in BIOSTAT-CHF. Patients had to 
have objective evidence of cardiac dysfunction documented either by left ventricular ejection fraction 
(LVEF) of ≤40%, or plasma concentrations of NT-proBNP >2,000pg/ml. We included patients with 
either SR or AF/atrial flutter at baseline for our analysis. Those with a pacemaker rhythm and 
unknown atrial rhythm (n=466), other rhythm (n=63) or unknown rhythm (n=111) were excluded. A 
flowchart of the selected patients is presented in Supplementary Figure 1. Patients were categorized 
into two groups based on LVEF assessed by transthoracic echocardiography: HFrEF (<40%) and 
HFpEF (≥50%). Patients with unknown LVEF were excluded (n=345). Patients with a LVEF between 
40-49% (HF with mid-range EF) were excluded in order to make a greater distinction between the two 
HF phenotypes (n=593). Quality of life (QoL) was assessed using the Kansas City Cardiomyopathy 
Questionnaire (KCCQ).(15) Higher scores indicated a better QoL. Primary outcome was time to all-
cause mortality. The study complies with the Declaration of Helsinki, medical ethics committee of 
participating centers approved the study, and all patients provided written informed consent.  
Definition of atrial fibrillation 
A standard 12-lead electrocardiogram (ECG) was performed at baseline. Patients were classified into 
AF or SR according to their heart rhythm at time of blood collection, registered on the baseline ECG.  
Biomarkers 
The Olink Cardiovascular III panel was used to create the biomarker profiles in the two HF 
phenotypes. This panel comprises 92 cardiovascular disease-related biomarkers, which were selected 
based on literature searches, disease association in the Coremine database, and in collaboration with 
experts within the cardiovascular field. Measurement of these 92 biomarkers was performed by Olink 
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Bioscience analysis service (Uppsala, Sweden), using the Proseek® multiplex Inflammatory
96*96 
kit.(16) The Proseek® reagents are based on the Proximity Extension Assay (PEA) technology, which 
binds 92 oligonucleotide-labeled antibody probe pairs to the target biomarker. For further 
quantification, real-time PCR was performed. Olink wizard and GenEx software were used for further 
data analysis. Proseek® data are presented as arbitrary units (AU) on a Log2 scale. Every marker was 
categorized by current literature in one or more categories.(17) The abbreviations and full names of 
the 92 biomarkers and their categories are presented in Supplementary Table 1.  
Statistical analyses 
Normally distributed variables were depicted as means ± standard deviation, non-normally distributed 
variables as median with the first and third quartile (Q1-Q3), categorical variables as numbers with 
percentages. Means of continuous variables were compared by one-way analysis of variance 
(ANOVA) or Kruskal-Wallis test, while categorical variables were compared by the χ2 test. Kaplan-
Meier survival curves were compared using the log-rank statistic. Cox regression models were used to 
adjust for the effect of covariates and to calculate hazard ratios (HR). The Cox proportional hazards 
assumption was assessed by visually inspecting plots of Schoenfeld residuals against time, which 
showed proportionality in both the total cohort, as in the two HF subgroups (HFrEF and HFpEF) 
separately. The median level of each biomarker in the AF group was divided by the median level of 
this biomarker in the SR group to produce a ratio. This ratio (converted into a percentage) was 
visualized in figure 1, where every bar represents this difference (%), which can either be positive 
(higher level in AF) or negative (higher level in SR). Interaction testing was performed to determine 
whether the effect of heart rhythm differed between the HF phenotypes, with regard to outcome 
(interaction term in the cox regression model) and with regard to every separate biomarker (interaction 
term in the linear regression model). We also tested three falsification hypotheses to see whether other 
important covariates gave similar biomarker patterns in HFrEF and HFpEF as found for heart rhythm. 
Rejection of these hypotheses would strengthen the fact that the biomarker profiles found for AF 
versus SR were specific for heart rhythm, and not importantly influenced by other confounders. These 
three hypotheses were formulated for age (below versus above the mean age in HFrEF and HFpEF), 
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renal disease (above versus below an estimated glomerular filtration rate (eGFR) of 60 
ml/min/1.73m
2
), and ischemic heart disease (previous myocardial infarction, percutaneous 
intervention and/or coronary artery bypass graft, ‘yes’ versus ‘no’). A substantial number of the 
previously mentioned definitions and analyses were added or adjusted during the review process. 
Therefore, the findings should be considered exploratory. In general, a two-tailed p-value of <0.05 was 
considered statistically significant. In the tables where the associations of 92 biomarkers were tested, 
the p-values were controlled for the false discovery rate using the Benjamini-Hochberg method. For 
testing interactions, a p-value of <0.1 was considered significant. 
 
Results 
Patient characteristics 
We studied a total of 2676 HF patients, of which 1703 were in SR (64%) and 971 had AF (36%). 
Baseline characteristics are presented in Table 1. These patients were further stratified in 2152 HFrEF 
patients, of which 1419 were in SR and 733 had AF, and 524 HFpEF patients, of which 286 were in 
SR and 238 had AF. The baseline characteristics of these 4 subgroups are presented in Table 2. In both 
HF phenotypes, patients with AF were significantly older than their counterparts in SR. Patients with 
AF and HFpEF were the oldest (79 ± 9 years) and patients in SR and HFrEF the youngest (69 ± 12 
years). Men were more likely to have AF and HFrEF, whereas a similar number of men and women 
had AF and HFpEF. In both HFrEF and HFpEF, patients with AF less often had a history of coronary 
artery disease (HFrEF: 51% in SR vs. 43% in AF, p=0.001 and HFpEF: 54% in SR vs. 28% in AF, 
p<0.001). Patients with HFpEF reported the lowest QoL, where no differences were seen between 
patients with AF and SR. However, in HFrEF, AF patients reported significantly lower QoL (Figure 
2).  
Biomarker profiles 
In HFrEF, the relative levels of 77 of 92 (84%) cardiovascular risk markers were higher in patients 
with AF than in those in SR, which resulted in a homogeneous risk marker pattern (Figure 1). This 
was in contrast to the pattern seen in HFpEF, where the risk marker profile of patients with AF versus 
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SR was much more scattered; 51 (55%) risk markers were higher in patients in SR and 36 (39%) in 
patients with AF (Figure 1). The median Log2 levels of the 92 biomarkers for SR and AF are 
presented in Supplementary Table 2 for HFrEF and Supplementary Table 3 for HFpEF. To find out 
whether these differences in biomarker profiles between HFrEF and HFpEF were importantly 
influenced by other covariates, interactions for every biomarker between rhythm group and HF 
phenotype were tested in a univariable and multivariable model. This resulted in a significant 
interaction between rhythm and HF phenotype in 44 biomarkers, of which 26 (59%) remained 
significant in the multivariable model (Supplementary Table 4).  
Apart from the differences seen in overall risk marker pattern when comparing HFrEF and HFpEF, 
several similarities were found when studying the top five markers with the largest difference between 
AF and SR (being highest in AF). In both HFrEF and HFpEF, NT-proBNP was the risk marker with 
the largest difference between AF and SR. Beyond NT-proBNP, two other markers were found in this 
top five in both HFrEF and HFpEF: ST2 and SPON1. A sensitivity analysis revealed no notable 
differences between patients who had a history of AF versus patients with AF on the baseline ECG. 
The falsification hypotheses about age, renal disease and ischemic heart disease showed homogeneous 
patterns with the most elevated risk markers in the group at risk (older, eGFR <60 and ischemic heart 
disease) in both HFrEF and HFpEF (Supplementary Figure 2), in contrast to the findings with AF 
versus SR in HFrEF and HFpEF.  
Outcome 
The median follow-up duration was 21 months (IQR 11-32 months). AF was associated with increased 
mortality risk (HR 1.44; 95% confidence interval [95%CI] 1.25-1.66, p<0.001) in the total cohort 
(Figure 3) and in the HF phenotypes (HFrEF: HR 1.41; 95%CI 1.19-1.68, p<0.001 and HFpEF: HR 
1.39; 95%CI 1.05-1.83, p=0.022) (Figure 4). After adjustment for covariates, the association of AF on 
outcome remained significant in the total cohort (HR 1.27; 95%CI 1.09-1.48, p=0.002), but no longer 
in HFpEF (Table 3). However, there was no significant interaction between heart rhythm and the HF 
phenotypes on outcome (p=0.71). Of the previously mentioned top five biomarkers, NT-proBNP, ST2 
and SPON1 were all strongly associated with all-cause mortality for patients in SR and AF in both 
HFrEF and HFpEF (Supplementary Table 5). 
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Discussion 
In this study, the presence of AF was associated with a homogeneously elevated cardiovascular risk 
marker profile in patients with HFrEF, whereas in HFpEF, the presence of AF was associated with a 
much more scattered risk marker profile. These findings suggest that there might be differences in 
underlying pathophysiological mechanisms of AF in these two HF phenotypes. 
Patient characteristics 
Patients with AF reported a significantly lower QoL than patients in SR in HFrEF, whereas QoL was 
not influenced by heart rhythm among patients with HFpEF. Interestingly, patients with HFpEF 
reported the lowest QoL. In our view, the overall lower QoL in our HFpEF patients could be explained 
by the higher age and higher number of women.(18) However, after adjustment for age and sex, AF 
still had a significantly negative influence on QoL in HFrEF but not in HFpEF. The levels of NT-
proBNP of the patients with HFpEF were relatively high, also in the SR group, due to the natriuretic 
peptide entry criteria for patients with a LVEF>40% in BIOSTAT-CHF. This might reflect the 
inclusion of quite severe HFpEF in our cohort, which could have directly resulted in the lower QoL.  
Similar to previous studies, our study found that men are more likely to have AF, especially in 
HFrEF.(19,20) In HFpEF, where more women were included, the prevalence of AF in men and 
women was similar. Furthermore, patients without a history of coronary artery disease were more 
likely to have AF, in accordance with previous studies.(20-23) Exact mechanisms of the difference 
between the sexes and associations with etiology are yet to be discovered.  
Biomarker profiles 
The biomarker profiles of patients with AF versus SR revealed prominent differences between HFrEF 
and HFpEF. The great majority of these markers were elevated in patients with AF in HFrEF. We 
hypothesize that AF is a reflection of a more advanced disease state in HFrEF, since almost all of 
these markers are associated with worse prognosis. In contrast, in HFpEF, the risk marker profile was 
more scattered, with less than half of the biomarkers being more elevated in the AF group. AF may be 
a separate bystander along with a high prevalence of other comorbidities in HFpEF, instead of a 
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marker for disease severity. Furthermore, it is possible that a higher number of patients had prior AF 
before HFpEF developed, which is shown to have a better prognosis as compared to patients who 
develop AF after HF.(24,25) Another possible explanation is the misclassification of HF in patients 
with AF. The challenges of making an accurate diagnosis of symptomatic AF (without HF) versus 
HFpEF with concomitant AF have been previously discussed.(5,9) It is plausible that patients with AF 
but without actual HFpEF were included in this group. Furthermore, since AF itself raises natriuretic 
peptides, the NT-proBNP inclusion criterion above >2,000pg/ml in BIOSTAT-CHF may have led to 
inclusion of patients in SR having more severe HFpEF. Greater severity of HF in patients with HFpEF 
and SR is supported by their low QoL, high mortality rates and higher numbers of elevated risk 
markers compared to those in SR and HFrEF. 
Despite the differences between the biomarker profiles seen in the two HF phenotypes, several 
similarities were found. Three out of five markers with the largest differences between AF and SR 
patients were seen in both HFrEF and HFpEF. NT-proBNP, the marker with the largest difference 
between AF and SR in both HF phenotypes, is well known to be importantly influenced by AF. The 
other two markers in both HFrEF and HFpEF were ST2 and SPON1. Soluble ST2 is released from the 
myocardium and vascular endothelial cells in response to pressure and/or volume overload, which is 
seen in both HFrEF and HFpEF, and which is also more pronounced in patients with AF.(26) Spondin-
1 (SPON1) has been less explored in the cardiovascular field, but associations of this marker have 
been identified with incident HF, worsened systolic function and hypertension.(27) No specific 
literature has been found about SPON1 in AF, but this biomarker has been related to angiogenesis and 
other prothrombotic markers, which perhaps could be linked to the mechanisms of thrombogenesis 
seen in AF.(17,28) 
In HFrEF, the other two top five risk markers were neurogenic locus notch homolog protein 3 
(NOTCH 3) and matrix metalloproteinase-2 (MMP2), which were both categorized as markers of 
remodeling. The two other markers that were most pronounced in patients with AF and HFpEF, were 
platelet-derived growth factor subunit-A (PDGFSUBUNITA) and insulin-like growth factor-binding 
protein-1 (IGFBP1), which are both not cardiac-specific markers, and both are linked to cellular 
growth factors.(29) No specific information is available about the biology and relation between AF 
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and these two markers. Our findings encourage additional studies investigating the underlying 
mechanisms and the clinical relevance of our findings.  
Strengths 
The novelty of this study is the measurement of 92 both established and novel cardiovascular risk 
markers, which resulted in the comparison of the biomarker profiles in HFrEF versus HFpEF. 
BIOSTAT-CHF is a reflection of real world contemporary European HF patients, due to the inclusion 
of patients from eleven European countries, aiming for optimal HF treatment. Furthermore, the HF 
phenotypes were defined according to the latest ESC guidelines EF cutoffs.(30)  
Limitations 
The results of the current study are based on post hoc analyses. The sample size of HFpEF was smaller 
than in HFrEF, which could explain the differences found in outcome between HFrEF and HFpEF 
after adjustment for covariates. However, since there was no significant interaction between heart 
rhythm and HF phenotype, it is unlikely that a larger sample size of HFpEF would have resulted in a 
contrasting outcome of AF-HFpEF patients. As discussed above, misclassification of AF versus 
HFpEF is possible, patients with more severe HFpEF in SR may have been included due to the 
natriuretic peptide inclusion criterion of BIOSTAT-CHF. This inclusion criterion could also have 
resulted in positive confounding with higher event rates in the HFpEF group, therefore we did not 
directly compare AF-HFrEF with AF-HFpEF. Unfortunately, we have no information about patients 
developing AF during follow-up. Furthermore, there is a lack of data on the type of AF (e.g. 
paroxysmal, persistent, permanent) and on applied therapies for AF. The questionnaire used for 
assessing QoL is not generally used in AF cohorts, which could have led to ignorance of AF specific 
symptoms that can influence QoL.  
Conclusion 
This study revealed that the presence of AF was associated with a homogeneously elevated 
cardiovascular risk marker profile in patients with HFrEF, whereas in HFpEF, the presence of AF was 
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associated with a more scattered risk marker profile. These findings suggest that there might be 
differences in underlying pathophysiological mechanisms of AF in these two HF phenotypes. 
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Figure Legends 
Figure 1: Graphical representation of the risk marker profile in patients with SR versus AF in HFrEF 
(left) and HFpEF (right). A blue bar indicates a higher level of this marker in patients with AF, 
whereas a red bar reflects a higher level in patients in SR. The top five biomarkers with the largest 
difference between SR and AF were highlighted in blue, with the percentage indicating the magnitude 
of this difference.  
HFrEF=heart failure with reduced ejection fraction, HFpEF=heart failure with preserved ejection 
fraction, SR=sinus rhythm, AF=atrial fibrillation, MMP2=matrix metalloproteinase-2, 
NOTCH3=neurogenic locus notch homolog protein-3, NTPROBNP=N-terminal pro-B-type natriuretic 
peptide, SPON1=spondin-1, ST2=ST-2 protein, IGFBP1=insulin-like growth factor-binding protein-1, 
PDGFSUBUNITA=platelet-derived growth factor subunit-A. 
Figure 2. Quality of Life; KCCQ scores for patients in SR versus AF 
Figure 3. Kaplan-Meier analysis showing the survival of patients in SR versus AF 
Figure 4. Kaplan-Meier analysis showing the effect of AF on survival by HF phenotype 
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Table 1. Baseline characteristics of heart failure patients in SR and AF 
 Total cohort  
 Sinus rhythm  
n=1705 (64%) 
Atrial fibrillation 
n=971 (36%) 
p-value 
Clinical    
       Age (years) 70±12 75±10 <0.001 
       Women (%) 527 (31) 263 (27) 0.041 
       BMI (kg/m2) 28.0±5.9 28.6±5.9 0.009 
       NYHA (%)   0.003 
1 122 (8) 43 (5)  
2 749 (48) 407 (45)  
3 570 (37) 363 (40)  
4 117 (8) 85 (10)  
       LVEF, %  33±13 36±14 <0.001 
       Systolic blood pressure (mmHg) 126±22 124±21 0.161 
       Diastolic blood pressure (mmHg) 73±13 74±14 0.001 
       Heart rate (beats/minute) 76±18 90±26 <0.001 
History of (%)    
       Atrial fibrillation 273 (16) 864 (89) <0.001 
       Coronary artery disease* 874 (52) 379 (39) <0.001 
       Valvular surgery  87 (5) 96 (10) <0.001 
       Stroke  182 (11) 131 (14) 0.034 
       Hypertension 1017 (60) 586 (60) 0.756 
       Diabetes Mellitus  541 (32) 306 (32) 0.962 
       COPD  305 (18) 170 (18) 0.837 
       Renal disease  482 (29) 357 (37) <0.001 
Physical examination (%)    
       Rales  789 (48) 519 (55) <0.001 
       Edema  768 (54) 591 (69) <0.001 
       JVP  323 (26) 286 (40) <0.001 
       Hepatomegaly 141 (9) 131 (14) <0.001 
KCCQ    
       Functional status score 52 [32-75] 45 [27-64] <0.001 
       Clinical summary score 49 [30-71] 42 [24-61] <0.001 
       Overall score 50 [32-70] 43 [27-60] <0.001 
Laboratory data    
       NT-proBNP (ng/L) 2030 [613-5797] 3093 [1548-6287] <0.001 
       Creatinine (µmol/L) 97 [80-119] 101 [84-127] <0.001 
       TSH (mU/L) 1.8 [1.0-2.7] 1.9 [1.2-3.1] 0.025 
       fT4 (pmol/L) 15.3 [13.2-17.9] 15.7 [13.9-18.2] 0.018 
Medications (%)    
       ACE/ARB 1267 (74) 658 (68) <0.001 
       β-Blocker  1348 (79) 760 (78) 0.665 
       MRA  792 (47) 428 (44) 0.252 
       Diuretics  1701 (100) 961 (99) 0.014 
*Coronary artery disease: previous myocardial infarction, percutaneous coronary intervention and/or coronary artery bypass 
graft. BMI=body mass index, NYHA=New York Heart Association, LVEF=left ventricular ejection fraction, COPD=chronic 
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obstructive pulmonary disease, JVP=jugular venous pressure, KCCQ=Kansas City Cardiomyopathy Questionnaire, NT-
proBNP=N-terminal pro-B-type natriuretic peptide, TSH=thyroid stimulating hormone, fT4=free thyroxine, 
ACE=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker, MRA=mineralocorticoid receptor 
antagonist. 
 
 
 
Table 2. Baseline characteristics by HF phenotype comparing patients in SR and AF 
 HFrEF  HFpEF  
 SR 
 n=1419 (66%) 
AF 
n=733 (34%) 
p-value 
SR 
n=286 (55%) 
AF 
n=238 (45%) 
p-value 
Clinical       
       Age (years) 69±12 74±10 <0.001 75±10 79±9 <0.001 
       Women (%) 390 (27) 152 (21) 0.001 137 (48) 111 (47) 0.841 
       BMI (kg/m2) 27.7±5.6 28.4±5.6 0.015 29.4±6.9 29.5±6.8 0.861 
       NYHA (%)   0.005   0.796 
1 115 (9) 35 (5)  7 (3) 8 (4)  
2 650 (51) 325 (48)  99 (36) 82 (36)  
3 444 (35) 268 (40)  126 (46) 95 (42)  
4 73 (6) 45 (7)  44 (16) 40 (18)  
       LVEF, %  28±7 28±7 0.115 58 ± 6 58±7 0.857 
       Systolic blood pressure (mmHg) 124±22 123±21 0.318 133 ± 25 128±21 0.024 
       Diastolic blood pressure (mmHg) 74±13 76±13 0.001 67 ± 13 71±15 0.004 
       Heart rate (beats/min) 77±18 91±25 <0.001 73 ± 17 88±27 <0.001 
History of (%)       
       Atrial fibrillation  227 (16) 653 (89) <0.001 46 (16) 211 (89) <0.001 
       Coronary artery disease* 720 (51) 314 (43) 0.001 154 (54) 65 (28) <0.001 
       Valvular surgery  61 (4) 72 (10) <0.001 26 (9) 24 (10) 0.813 
       Stroke  132 (9) 93 (13) 0.019 50 (18) 38 (16) 0.746 
       Hypertension 814 (57) 428 (59) 0.682 203 (71) 158 (66) 0.300 
       Diabetes Mellitus  443 (31) 221 (30) 0.646 98 (34) 85 (36) 0.767 
       COPD  230 (16) 121 (17) 0.908 75 (26) 49 (21) 0.153 
       Renal disease  355 (25) 250 (34) <0.001 127 (46) 107 (46) 1.000 
Physical examination (%)       
       Rales  647 (47) 368 (52) 0.032 142 (51) 151 (65) 0.003 
       Edema  596 (50) 428 (67) <0.001 172 (68) 163 (74) 0.196 
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       JVP  256 (25) 204 (39) <0.001 67 (31) 82 (42) 0.025 
       Hepatomegaly  131 (9) 113 (16) <0.001 10 (4) 18 (8) 0.089 
KCCQ       
       Functional status score 55 [36-75] 46 [27-66] <0.001 39 [23-63] 38 [21-58] 0.530 
       Clinical summary score 51 [32-73] 44 [26-63] <0.001 39 [20-60] 37 [23-56] 0.691 
       Overall score 52 [35-71] 45 [29-63] <0.001 42 [25-59] 39 [25-53] 0.365 
Laboratory data       
       NT-proBNP (ng/L) 2642 [855-6725] 3573 [1853-7127] <0.001 802 [261-3092] 2359 [1136-4799] <0.001 
       Creatinine (µmol/L) 97 [80-118] 104 [87-130] <0.001 95 [74-124] 95 [78-122] 0.751 
       TSH (mU/L) 1.8 [1.1-2.8] 1.9 [1.3-3.2] 0.009 1.6 [1.0-2.6] 1.8 [0.9-2.9] 0.695 
       fT4 (pmol/L) 15.1 [13.0-17.8] 15.5 [13.7-18.0] 0.055 15.7 [13.8-18.0] 16.0 [14.1-18.6] 0.328 
Medications (%)       
       ACE/ARB 1079 (76) 532 (73) 0.089 188 (66) 126 (53) 0.004 
       β-Blocker  1168 (82) 607 (83) 0.819 180 (63) 153 (64) 0.819 
       MRA  738 (52) 365 (50) 0.353 54 (19) 63 (27) 0.049 
       Diuretics  1416 (100) 729 (100) 0.373 285 (100) 232 (98) 0.076 
* Coronary artery disease: previous myocardial infarction, percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG).  
HFrEF=heart failure with reduced ejection fraction, HFpEF=heart failure with preserved ejection fraction, BMI=body mass index, NYHA=New York Heart Association, LVEF=left ventricular 
ejection fraction, COPD=chronic obstructive pulmonary disease, JVP=jugular venous pressure, KCCQ=Kansas City Cardiomyopathy Questionnaire, NT-proBNP=N-terminal pro-B-type 
natriuretic peptide, TSH=thyroid stimulating hormone, fT4=free thyroxine, ACE=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker, MRA=mineralocorticoid receptor 
antagonist.
Table 3. Multivariable cox regression analysis for all-cause mortality by HF phenotype 
 Univariable analysis Multivariable analysis* Multivariable analysis** 
 HR (95% CI), AF vs. SR p-value HR (95% CI), AF vs. SR p-value HR (95% CI), AF vs. SR p-value 
HFrEF 1.41 (1.19-1.68) <0.001 1.24 (1.04-1.47) 0.015 1.28 (1.07-1.53) 0.007 
HFpEF 1.39 (1.05-1.83) 0.022 1.11 (0.83-1.48) 0.480 1.10 (0.81-1.49) 0.550 
Overall 1.44 (1.25-1.66) <0.001 1.22 (1.05-1.41) 0.009 1.27 (1.09-1.48) 0.002 
P-value for interaction: 0.71 
*Adjusted for age 
**Adjusted for age, sex, body mass index, previous myocardial infarction/percutaneous intervention and/or coronary artery bypass graft, hypertension and renal disease.  
HR=hazard ratio, CI=confidence interval, AF=atrial fibrillation, SR=sinus rhythm, HFrEF=heart failure with reduced ejection fraction, HFpEF=heart failure with preserved ejection fraction. 
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Figure 3.  
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Figure 4.  
 
 
 
Supplementary files 
Supplementary Figure 1. Flowchart  
 
 
 
 
 
 
 
 
29 
 
Supplementary Figure 2. Visualizing three falsification hypotheses for age, renal disease 
and ischemic heart disease in HFrEF and HFpEF 
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Supplementary Table 1. List of 92 biomarkers OLINK, CVD III panel 
ALCAM = CD166 antigen (Other; tumor marker) 
APN = Aminopeptidase N (Angiogenesis) 
AXL = Tyrosine-protein kinase receptor UFO (Inflammation, immune system, cardiomyocyte injury, 
angiogenesis) 
AZU1 = Azurocidin-1 (Inflammation) 
BMLHYDROLASE = Bleomyocin hydrolase (Other / experimental) 
BP18 = Interleukin-18 binding protein (Inflammation, immune system) 
CASP3 = Caspase-3 (Cell-death/Apoptosis) 
CBP1 = Carboxypeptidase B1 (Metabolism) 
CCL15 = C-C motif chemokine 15 (Inflammation) 
CCL16 = C-C motif chemokine 16 (Inflammation) 
CCL22 = C-C motif chemokine 22 (Inflammation) 
CCL24 = C-C motif chemokine 24 (Inflammation) 
CD163 = Scavenger receptor cysteine-rich type 1 protein m130 (Oxidative stress, inflammation, immune system) 
CD93 = Complement component C1q receptor (Atherosclerosis) 
CDH5 = Cadherin-5 (Other/Ion-channel (calcium)) 
CHI3L1 = Chitinase-3-like protein 1 (Inflammation, immune system) 
CHIT1 = Chitotriosidase-1 (Atherosclerosis) 
CNTN1 = Contactin-1 (Other; tumor marker) 
COL1A1 = Collagen alpha-1 (I) chain (Remodeling) 
CPA1 = Carboxypeptidase A1 (Metabolism) 
CSTB = Cystatin-B (Inflammation, immune system) 
CTSD = Cathepsin D (Oxidative stress) 
CTSZ = Cathepsin Z (Other; tumor marker) 
CXCL16 = C-X-C motif chemokine 16 (Inflammation, other; renal damage) 
DLK1 = Protein delta homolog 1 (Other; growth factor) 
EGFR2 = Epidermal growth factor receptor (Angiogenesis, inflammation) 
EPCAM = Epithelial cell adhesion molecule (Other; tumor marker) 
EPHB4 = Ephrin type-B receptor 4 (Angiogenesis) 
FABP4 = Fatty acid-binding protein, adipocyte (Inflammation, atherosclerosis) 
FAS = Tumor necrosis factor receptor superfamily member 6 (Inflammation, immune system, apoptosis) 
GAL3 = Galectin-3 (Remodeling; fibrotic marker) 
GAL4 = Galectin-4 (Remodeling) 
GDF15 = Growth/differentiation factor 15 (Inflammation) 
GRN = Granulins (Inflammation, remodeling) 
ICAM2 = Intercellular adhesion molecule 2 (Inflammation, immune system) 
IGFBP1 = Insulin-like growth factor-binding protein 1 (Remodeling, inflammation, metabolic marker) 
IGFBP2 = Insulin-like growth factor-binding protein 2 (Remodeling) 
IGFBP7 = Insulin-like growth factor-binding protein 7 (Remodeling) 
IL17RA = Interleukin-17 receptor A (Inflammation, immune system) 
IL1RT1 = Interleukin-1 receptor type 1 (Inflammation, immune system) 
IL1RT2 = Interleukin-1 receptor type 2 (Inflammation, immune system) 
IL2RA = Interleukin-2 receptor subunit Alpha (Inflammation, immune system) 
IL6RA = Interleukin-6 receptor subunit Alpha (Inflammation, immune system) 
ITGB2 = Integrin beta-2 (Remodeling, angiogenesis) 
JAMA = Junctional adhesion molecule A (Inflammation, immune system) 
KLK6 = Kallikrein-6 (Inflammation, immune system) 
LDLR = Low-density lipoprotein receptor (Artherosclerosis) 
LTBR = Lympotoxin-beta receptor (Inflammation, immune system, Artherosclerosis) 
MB = Myoglobin (Cardiomyocyte stretch/injury) 
MCP1 = Monocyte chemotactic protein 1 (Inflammation, immune system/atherosclerosis) 
MEPE = Matrix extracellular phosphoglycoprotein (Other; electrolyte balance) 
MMP2 = Matrix metalloproteinase-2 (Remodeling) 
MMP3 = Matrix metalloproteinase-3 (Remodeling/angiogenesis) 
MMP9 = Matrix metalloproteinase-9 (Remodeling/angiogenesis) 
MPO = Myeloperoxidase (Inflammation, immune system) 
NOTCH3 = Neurogenic locus notch homolog protein 3 (Remodeling) 
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NTPROBNP = N-terminal prohormone of brain-type natriuretic peptide (Cardiomyocyte stretch/injury)  
OPG = Osteoprotegerin (Inflammation, immune system) 
OPN = Osteopontin (Inflammation, immune system, atherosclerosis, fibrosis) 
PAI = Plasminogen activator inhibitor 1 (Angiogenesis, other; thrombosis) 
PCSK9 = Proprotein convertase subtillisin/kexin type 9 (Metabolic marker) 
PDGFSUBUNITA = Platelet-derived growth factor subunit A (Other; growth factor/developmental protein) 
PECAM1 = Platelet endothelial cell adhesion molecule (Angiogenesis, endothelial function) 
PGLYRP1 = Peptidoglycan recognition protein 1 (Inflammation, immune system) 
PI3 = Elafin (Inflammation, immune system) 
PLC = Perlecan (Angiogenesis) 
PON3 = Paraoxonase (Atherosclerosis, metabolic marker) 
PRTN3 = Myeloblastin (Inflammation, immune system) 
PSPD = Pulmonary surfactant-associated protein D (Inflammation, immune system) 
RARRES2 = Retinoic acid receptor responder protein 2 (Metabolic marker and inflammation, immune system) 
RETN = Resistin (Metabolic marker) 
SCGB3A2 = Secretoglobin family 3A member 2 (Remodeling, fibrosis) 
SELE = E-selectin (Endothelial function) 
SELP = P-selectin (Inflammation, immune system) 
SHPS1 = Tyrosine-protein phosphatase non-receptor type substrate 1 (Endothelial function, inflammation, immune 
system) 
SPON1 = Spondin-1 (Angiogenesis) 
ST2 = ST-2 protein (Remodeling, inflammation, immune system, oxidative stress, cardiomyocyte stretch/injury, 
angiogenesis) 
TFF3 = Trefoil factor 3 (Inflammation, immune system) 
TFPI = Tissue factor pathway inhibitor (Haematological marker) 
TIMP4 = Metalloproteinase inhibitor 4 (Remodeling/angiogenesis) 
TLT2 = Trem-like transcript 2 protein (Inflammation, immune system) 
TNFR1 = Tumor necrosis factor receptor 1 (Inflammation, immune system, apoptosis, endothelial function) 
TNFR2 = Tumor necrosis factor receptor 2 (Apoptosis, inflammation, immune system)  
TNFRSF14 = Tumor necrosis factor receptor superfamily member 14 (Inflammation, immune system, apoptosis) 
TNFSF13B = Tumor necrosis factor ligand superfamily member 13B (Inflammation, immune system) 
TNRSF10C = Tumor necrosis factor receptor superfamily member 10C (Apoptosis, inflammation, immune 
system) 
TPA = Tissue-type plasminogen activator (Haematological marker) 
TR = Transferrin receptor protein 1 (Haematological marker) 
TRAP = Tartrate-resistant acid phosphatase type 5 (Inflammation, immune system) 
UPA = Urokinase plasminogen activator (Hemostasis, angiogenesis, fibrosis/remodeling, immune system, 
inflammation) 
UPAR = Urokinase plasminogen activator surface receptor (Hemostasis, angiogenesis, fibrosis/remodeling, 
immune system, inflammation) 
VWF = von Willebrand factor (Hemostasis, endothelial dysfunction) 
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Supplementary Table 2. Median levels (Q1, Q3) of the 92 biomarkers for sinus rhythm 
and atrial fibrillation in HFrEF 
Biomarker Log2 
median 
level SR 
Q1 Q3 Log2 
median 
level AF 
Q1 Q3 % Difference 
AF-SR 
P-value 
ALCAM 4.28 3.85 4.65 4.37 3.9 4.73 2.1 0.012 
APN 4.32 3.9 4.75 4.53 4.09 4.95 4.9 <0.001 
AXL 7.22 6.76 7.61 7.34 6.87 7.75 1.7 0.003 
AZU1 1.87 1.46 2.4 2.04 1.47 2.57 9.1 <0.001 
BMLHYDROLASE 4.57 4.17 4.94 4.68 4.25 5.06 2.4 0.003 
BP18 5.8 5.28 6.31 5.85 5.38 6.38 0.9 0.104 
CASP3 6.54 5.73 7.72 6.5 5.63 7.6 -0.6 0.299 
CBP1 3.47 2.85 4.12 3.62 2.98 4.3 4.3 <0.001 
CCL15 6.63 6.14 7.15 6.69 6.22 7.27 0.9 0.044 
CCL16 5.54 4.97 6.02 5.67 5.17 6.22 2.3 <0.001 
CCL22 1.67 1.11 2.3 1.54 1.06 2.16 -7.8 0.068 
CCL24 4.92 4.25 5.62 4.99 4.3 5.71 1.4 0.186 
CD163 6.93 6.4 7.4 7 6.53 7.5 1 0.010 
CD93 9.05 8.58 9.42 9.07 8.64 9.49 0.2 0.145 
CDH5 2.92 2.42 3.39 3.02 2.51 3.47 3.4 0.012 
CHI3L1 5.62 4.77 6.54 5.84 5.09 6.59 3.9 0.003 
CHIT1 2.44 1.69 3.22 2.5 1.7 3.19 2.5 0.591 
CNTN1 2.04 1.58 2.44 2.12 1.63 2.52 3.9 0.010 
COL1A1 1.71 1.26 2.16 1.82 1.32 2.21 6.4 0.006 
CPA1 3.83 3.19 4.51 4 3.33 4.69 4.4 <0.001 
CSTB 4.56 3.9 5.14 4.74 4.18 5.41 3.9 <0.001 
CTSD 3.25 2.8 3.71 3.34 2.9 3.8 2.8 0.015 
CTSZ 4.34 3.86 4.78 4.34 3.86 4.78 0 0.836 
CXCL16 5.68 5.23 6.08 5.72 5.29 6.14 0.7 0.158 
DLK1 4.32 3.72 4.99 4.39 3.71 5.02 1.6 0.346 
EGFR2 0.74 0.4 1.07 0.79 0.45 1.07 6.8 0.552 
EPCAM 3.09 2.42 3.85 2.91 2.26 3.64 -5.8 0.003 
EPHB4 1.58 1.21 1.99 1.62 1.3 2.05 2.5 0.121 
FABP4 5.21 4.34 6.14 5.53 4.75 6.41 6.1 <0.001 
FAS 4.28 3.84 4.72 4.32 3.91 4.79 0.9 0.158 
GAL3 4.64 4.14 5.05 4.66 4.17 5.04 0.4 0.707 
GAL4 3.12 2.59 3.65 3.19 2.61 3.72 2.2 0.282 
GDF15 4.9 4.24 5.6 5.14 4.5 5.9 4.9 0.003 
GRN 3.14 2.75 3.49 3.23 2.82 3.58 2.9 0.003 
ICAM2 4.44 3.98 4.92 4.56 4.03 5.01 2.7 0.019 
IGFBP1 4.52 3.48 5.47 4.92 3.96 5.77 8.8 <0.001 
IGFBP2 7.68 7.02 8.3 7.91 7.3 8.49 3 <0.001 
IGFBP7 3.7 3.17 4.21 4.07 3.49 4.61 10 <0.001 
IL_17RA 3.39 2.89 3.82 3.49 3.01 3.88 2.9 0.043 
IL1RT1 5.99 5.54 6.41 6.1 5.63 6.54 1.8 <0.001 
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IL1RT2 4.16 3.73 4.57 4.23 3.86 4.64 1.7 0.004 
IL2RA 3.77 3.24 4.29 3.76 3.22 4.29 -0.3 0.768 
IL6RA 10.24 9.82 10.66 10.2 9.84 10.63 -0.4 0.948 
ITGB2 4.43 4.04 4.84 4.48 4.05 4.87 1.1 0.156 
JAMA 4.48 3.95 5.22 4.62 4 5.22 3.1 0.209 
KLK6 2.75 2.37 3.21 2.79 2.37 3.25 1.5 0.582 
LDLR 3.27 2.74 3.85 3.04 2.49 3.6 -7 <0.001 
LTBR 3.05 2.61 3.56 3.15 2.71 3.69 3.3 0.004 
MB 6.22 5.64 6.92 6.42 5.78 7.1 3.2 <0.001 
MCP1 2.38 1.96 2.79 2.47 2.04 2.89 3.8 0.004 
MEPE 2.37 1.87 2.89 2.42 1.92 2.91 2.1 0.276 
MMP2 2.87 2.34 3.43 3.19 2.62 3.66 11.1 <0.001 
MMP3 6.85 6.24 7.51 7.06 6.42 7.67 3.1 <0.001 
MMP9 3.24 2.59 3.96 3.44 2.68 4.07 6.2 0.006 
MPO 3.65 3.22 4.06 3.73 3.27 4.1 2.2 0.101 
NOTCH3 3.23 2.75 3.69 3.61 3.1 4.06 11.8 <0.001 
NTPROBNP 2.82 1.81 3.91 3.3 2.49 4.19 17 <0.001 
OPG 2.73 2.3 3.19 2.85 2.39 3.3 4.4 <0.001 
OPN 4.89 4.29 5.49 5.11 4.55 5.72 4.5 <0.001 
PAI 4.9 4.04 5.73 4.99 4.16 5.81 1.8 0.114 
PCSK9 1.98 1.59 2.34 1.94 1.57 2.35 -2 0.406 
PDGFSUBUNITA 1.6 0.9 2.57 1.6 0.93 2.59 0 0.465 
PECAM1 4.27 3.79 4.82 4.4 3.91 4.84 3 0.013 
PGLYRP1 6.67 6.14 7.19 6.77 6.28 7.26 1.5 0.018 
PI3 3.17 2.6 3.84 3.24 2.66 3.84 2.2 0.348 
PLC 6.46 6.02 6.95 6.66 6.21 7.1 3.1 <0.001 
PON3 4.59 3.87 5.31 4.47 3.74 5.11 -2.6 0.004 
PRTN3 4.04 3.57 4.53 4.13 3.67 4.6 2.2 0.018 
PSPD 2.2 1.59 2.79 2.3 1.71 2.86 4.5 0.042 
RARRES2 11.15 10.81 11.47 11.1 10.7 11.44 -0.4 0.186 
RETN 6.02 5.54 6.51 6.12 5.65 6.63 1.7 0.017 
SCGB3A2 2.21 1.6 2.9 2.38 1.71 3.18 7.7 0.003 
SELE 1.69 1.14 2.25 1.78 1.2 2.26 5.3 0.109 
SELP 8.28 7.69 8.86 8.23 7.65 8.83 -0.6 0.367 
SHPS1 3.05 2.57 3.52 3.15 2.63 3.59 3.3 0.025 
SPON1 1.68 1.29 2.08 1.91 1.42 2.41 13.7 <0.001 
ST2 3.65 3.08 4.37 4.03 3.45 4.79 10.4 <0.001 
TFF3 5.22 4.67 5.86 5.36 4.87 6 2.7 <0.001 
TFPI 7.89 7.45 8.26 7.86 7.39 8.22 -0.4 0.178 
TIMP4 4.52 4 5.02 4.68 4.18 5.21 3.5 <0.001 
TLT2 3.68 3.2 4.11 3.65 3.13 4.12 -0.8 0.711 
TNFR1 4.87 4.33 5.45 5.03 4.44 5.58 3.3 0.003 
TNFR2 4.41 3.87 4.96 4.49 3.95 5.07 1.8 0.025 
TNFRSF14 4.26 3.76 4.74 4.3 3.82 4.84 0.9 0.114 
TNFSF13B 5.52 5.02 5.99 5.6 5.05 6.09 1.4 0.042 
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TNRSF10C 5.43 4.92 5.91 5.46 4.92 5.99 0.6 0.245 
TPA 4.8 4.13 5.66 5.06 4.31 5.92 5.4 <0.001 
TR 4.92 4.42 5.48 5.13 4.53 5.65 4.3 <0.001 
TRAP 4.61 4.14 5.07 4.4 3.93 4.87 -4.6 <0.001 
UPA 4.03 3.6 4.41 4.13 3.69 4.49 2.5 0.005 
UPAR 4.13 3.66 4.61 4.27 3.84 4.8 3.4 <0.001 
VWF 5.85 5.17 6.84 6.04 5.29 6.87 3.2 0.048 
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Supplementary Table 3. Median levels (Q1, Q3) of the 92 biomarkers for sinus rhythm 
and atrial fibrillation in HFpEF 
Biomarker 
Log2 
median 
level SR 
Q1 Q3 Log2 
median 
level AF 
Q1 Q3 % Difference 
AF-SR 
p-value 
ALCAM 4.62 4.26 4.89 4.62 4.16 4.93 0 0.969 
APN 4.55 4.16 4.83 4.6 4.17 5.02 1.1 0.466 
AXL 7.57 7.19 7.92 7.53 7.09 7.98 -0.5 0.911 
AZU1 2.03 1.67 2.41 2.01 1.52 2.48 -1 0.771 
BMLHYDROLASE 4.7 4.34 4.99 4.66 4.36 5.04 -0.9 0.921 
BP18 6.36 5.95 6.79 6.29 5.78 6.76 -1.1 0.323 
CASP3 6.25 5.57 6.97 6.28 5.43 7.13 0.5 0.969 
CBP1 3.58 3.04 4.27 3.74 3.11 4.37 4.5 0.559 
CCL15 6.96 6.5 7.44 6.92 6.45 7.46 -0.6 0.911 
CCL16 5.85 5.44 6.35 5.82 5.19 6.22 -0.5 0.111 
CCL22 1.9 1.4 2.45 1.91 1.23 2.39 0.5 0.617 
CCL24 5.33 4.46 6.08 5.01 4.45 5.84 -6 0.235 
CD163 7.34 6.88 7.69 7.39 6.87 7.82 0.7 0.630 
CD93 9.33 8.95 9.62 9.32 8.84 9.68 -0.1 0.713 
CDH5 3.27 2.86 3.63 3.29 2.72 3.7 0.6 0.911 
CHI3L1 6.36 5.48 7.18 6.4 5.56 7.27 0.6 0.916 
CHIT1 2.84 2.09 3.56 2.66 2.04 3.59 -6.3 0.697 
CNTN1 2.37 1.86 2.71 2.34 1.89 2.75 -1.3 0.969 
COL1A1 2.03 1.63 2.43 2.1 1.47 2.52 3.4 0.759 
CPA1 4.13 3.48 4.76 4.19 3.48 4.8 1.5 0.882 
CSTB 5.04 4.43 5.71 4.97 4.41 5.67 -1.4 0.921 
CTSD 3.54 3.15 3.93 3.51 3.07 3.91 -0.8 0.709 
CTSZ 4.8 4.4 5.17 4.66 4.21 5.1 -2.9 0.110 
CXCL16 6.09 5.69 6.43 5.97 5.62 6.35 -2 0.081 
DLK1 4.98 4.43 5.57 4.72 4.16 5.31 -5.2 0.039 
EGFR2 0.92 0.68 1.18 0.86 0.49 1.14 -6.5 0.111 
EPCAM 3.42 2.77 4.15 3.24 2.55 3.78 -5.3 0.040 
EPHB4 2.04 1.69 2.41 1.97 1.6 2.37 -3.4 0.279 
FABP4 5.93 5.13 6.74 5.94 5.23 6.78 0.2 0.882 
FAS 4.72 4.32 5.08 4.61 4.18 4.97 -2.3 0.127 
GAL3 5.05 4.61 5.38 4.9 4.39 5.23 -3 0.038 
GAL4 3.41 2.92 3.96 3.34 2.83 3.85 -2.1 0.260 
GDF15 5.42 4.76 6.03 5.55 4.98 6.08 2.4 0.248 
GRN 3.42 3.13 3.74 3.36 3.04 3.76 -1.8 0.818 
ICAM2 4.86 4.43 5.24 4.91 4.35 5.3 1 0.696 
IGFBP1 4.52 3.54 5.5 4.99 3.91 5.93 10.4 0.012 
IGFBP2 8.14 7.47 8.72 8.25 7.71 8.79 1.4 0.235 
IGFBP7 4 3.54 4.37 4.28 3.69 4.75 7 0.047 
IL_17RA 3.65 3.19 4.07 3.66 3.15 4.04 0.3 0.971 
IL1RT1 6.36 5.94 6.71 6.32 5.91 6.78 -0.6 0.969 
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IL1RT2 4.41 4.06 4.82 4.36 4.05 4.77 -1.1 0.713 
IL2RA 4.27 3.8 4.78 4.18 3.68 4.74 -2.1 0.502 
IL6RA 10.58 10.18 10.99 10.45 10.01 10.82 -1.2 0.038 
ITGB2 4.58 4.16 4.94 4.49 4.1 4.86 -2 0.544 
JAMA 4.57 4.11 5.01 4.55 4.06 5.22 -0.4 0.800 
KLK6 3.14 2.57 3.54 2.96 2.52 3.44 -5.7 0.114 
LDLR 3.67 3.09 4.15 3.16 2.56 3.76 -13.9 <0.001 
LTBR 3.63 3.2 4.08 3.57 3.07 4.1 -1.7 0.744 
MB 6.85 6.29 7.54 6.78 6.19 7.39 -1 0.552 
MCP1 2.73 2.37 3.02 2.7 2.31 3.03 -1.1 0.552 
MEPE 2.74 2.32 3.22 2.58 2.06 3.13 -5.8 0.082 
MMP2 3.12 2.72 3.62 3.28 2.75 3.77 5.1 0.235 
MMP3 7.24 6.61 7.9 7.17 6.55 7.68 -1 0.544 
MMP9 3.32 2.61 4.06 3.19 2.53 3.84 -3.9 0.248 
MPO 3.93 3.55 4.27 3.85 3.4 4.28 -2 0.679 
NOTCH3 3.63 3.19 4.03 3.84 3.35 4.3 5.8 0.032 
NTPROBNP 2.33 1.45 3.44 3.12 2.33 3.85 33.9 <0.001 
OPG 3.13 2.7 3.44 3.16 2.7 3.56 1 0.713 
OPN 5.4 4.84 5.87 5.47 4.84 5.88 1.3 0.771 
PAI 4.52 3.74 5.42 4.62 3.9 5.29 2.2 0.911 
PCSK9 2.21 1.8 2.54 2.08 1.67 2.47 -5.9 0.248 
PDGFSUBUNITA 1.01 0.59 1.8 1.23 0.78 1.78 21.8 0.111 
PECAM1 4.42 4.05 4.7 4.45 4 4.84 0.7 0.466 
PGLYRP1 7.07 6.61 7.6 7.07 6.47 7.43 0 0.382 
PI3 3.52 2.88 4.29 3.52 2.89 4.17 0 0.780 
PLC 6.88 6.5 7.32 6.88 6.48 7.33 0 0.956 
PON3 5.02 4.22 5.66 4.64 3.98 5.31 -7.6 <0.001 
PRTN3 4.36 3.9 4.85 4.41 3.88 5 1.1 0.771 
PSPD 2.37 1.82 3 2.42 1.86 2.92 2.1 0.969 
RARRES2 11.41 11.06 11.62 11.24 10.94 11.58 -1.5 0.040 
RETN 6.41 5.99 6.95 6.35 5.79 6.95 -0.9 0.456 
SCGB3A2 2.69 2.12 3.42 2.77 2.14 3.41 3 0.709 
SELE 2.12 1.64 2.61 2.03 1.46 2.58 -4.2 0.679 
SELP 8.38 7.87 8.78 8.17 7.72 8.75 -2.5 0.276 
SHPS1 3.48 3 3.87 3.43 2.98 3.89 -1.4 0.891 
SPON1 2 1.61 2.34 2.19 1.74 2.59 9.5 0.031 
ST2 4.12 3.66 4.69 4.41 3.76 5.1 7 0.039 
TFF3 5.7 5.22 6.37 5.76 5.23 6.36 1.1 0.911 
TFPI 8.03 7.73 8.32 7.86 7.48 8.28 -2.1 0.020 
TIMP4 5.01 4.47 5.41 5.08 4.59 5.48 1.4 0.550 
TLT2 4.06 3.66 4.53 3.92 3.41 4.4 -3.4 0.038 
TNFR1 5.55 5.01 6.1 5.43 4.93 6.03 -2.2 0.696 
TNFR2 5.09 4.53 5.53 4.97 4.41 5.6 -2.4 0.552 
TNFRSF14 4.75 4.21 5.26 4.63 4.11 5.19 -2.5 0.382 
TNFSF13B 5.87 5.45 6.29 5.94 5.36 6.38 1.2 0.709 
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TNRSF10C 5.99 5.42 6.33 5.85 5.28 6.21 -2.3 0.110 
TPA 4.81 4.3 5.66 5.07 4.41 5.89 5.4 0.111 
TR 5.18 4.6 5.68 5.26 4.72 5.86 1.5 0.248 
TRAP 5.16 4.79 5.5 4.68 4.22 5.17 -9.3 <0.001 
UPA 4.26 3.91 4.61 4.33 3.9 4.68 1.6 0.646 
UPAR 4.58 4.11 5.07 4.58 4.16 5.11 0 0.808 
VWF 5.94 5.4 6.67 6.11 5.54 6.73 2.9 0.334 
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Supplementary Table 4. List of biomarkers with significant interactions between heart 
rhythm (AF/SR) and heart failure phenotype (HFrEF/HFpEF); univariable and 
multivariable linear regression model. 
Biomarker Model 1* Model 2** 
AXL 0.052 0.116 
BP18 0.032 0.182 
CCL16 <0.001 <0.001 
CCL24 0.029 0.042 
CSTB 0.032 0.133 
CTSD 0.057 0.101 
CTSZ 0.035 0.199 
CXCL16 0.010 0.032 
DLK1 0.006 0.065 
EGFR2 0.023 0.027 
EPHB4 0.008 0.064 
FABP4 0.012 0.028 
FAS 0.019 0.068 
GAL3 0.018 0.081 
GAL4 0.070 0.394 
GRN 0.055 0.110 
IL1RT1 0.063 0.164 
IL1RT2 0.054 0.072 
IL6RA 0.067 0.170 
KLK6 0.004 0.042 
LDLR 0.018 0.019 
LTBR 0.027 0.138 
MB 0.010 0.074 
MCP1 0.003 0.011 
MEPE 0.002 0.020 
MMP2 0.043 0.062 
MMP3 0.002 0.015 
MMP9 0.011 0.008 
NOTCH3 0.038 0.054 
OPN 0.022 0.068 
PGLYRP1 0.030 0.162 
PLC 0.015 0.091 
PON3 0.031 0.015 
RETN 0.028 0.177 
TFF3 0.081 0.295 
TFPI 0.075 0.065 
TIMP4 0.095 0.174 
TLT2 0.008 0.051 
TNFR1 0.039 0.246 
TNFR2 0.038 0.240 
TNFRSF14 0.031 0.215 
TNRSF10C 0.022 0.080 
TRAP 0.009 0.032 
UPAR 0.077 0.241 
 
*Model 1: interaction for heart rhythm and heart failure phenotype tested for the 92 biomarkers 
**Model 2: interaction for heart rhythm and heart failure phenotype tested in a multivariable model, including 
age, sex, CAD, BMI, renal disease and hypertension 
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Supplementary Table 5. Top 5 biomarkers with largest difference between AF and SR in 
HFrEF and HFpEF, as prognostic predictors of all-cause mortality 
 
HFrEF 
 Sinus rhythm (n=1419) Atrial fibrillation (n=733) 
HR 95% CI P-value HR 95% CI P-value 
NT-proBNP 1.51 1.41-1.63 <0.001 1.42 1.30-1.57 <0.001 
ST2 1.71 1.54-1.90 <0.001 1.59 1.40-1.81 <0.001 
SPON1 1.76 1.53-2.02 <0.001 1.32 1.10-1.57 0.003 
MMP2 1.51 1.30-1.75 <0.001 1.12 0.94-1.33 0.20 
NOTCH3 1.50 1.30-1.73 <0.001 1.02 0.85-1.22 0.85 
HFpEF 
 Sinus rhythm (n=286) Atrial fibrillation (n=238) 
HR 95% CI P-value HR 95% CI P-value 
NT-proBNP 1.53 1.37-1.71 <0.001 1.52 1.27-1.81 <0.001 
ST2 1.72 1.42-2.08 <0.001 1.58 1.29-1.94 <0.001 
SPON1 1.76 1.32-2.34 <0.001 1.97 1.44-2.69 <0.001 
IGFBP1 1.54 1.31-1.82 <0.001 1.42 1.22-1.66 <0.001 
PDGFSUBUNITA 1.13 0.92-1.98 0.26 1.04 0.82-1.30 0.76 
 
AF = atrial fibrillation, SR = sinus rhythm, HFrEF = heart failure with reduced ejection fraction, HFpEF = heart failure with 
preserved ejection fraction, HR = hazard ratio, CI = confidence interval, NT-proBNP = = N-terminal pro B-type natriuretic 
peptide, ST2 = ST-2 protein, SPON1 = Spondin-1, MMP2 = Matrix metalloproteinase-2, NOTCH3 = Neurogenic locus notch 
homolog protein 3, IGFBP1 = Insulin-like growth factor-binding protein, PDGFSUBUNITA = Platelet-derived growth factor 
subunit A. 
